CHRS
Coherus Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.35
+9.76%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 2.68x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 3.43x
- Price / sales
- 4.09x
- Price / cash flow
- -0.86x
Enterprise value
- Enterprise value
- $141.0M
- EV / sales
- 2.77x
- EV / EBITDA
- -0.95x
- EV / EBIT
- -0.90x
- Market cap
- $208.6M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026